Jakafi (Ruxolitinib) 5 mg – Rulicent Tablets for Myelofibrosis
Jakafi 5 mg, containing Ruxolitinib, is a specialty medicine used to manage several chronic bone marrow disorders. As a selective JAK1/JAK2 inhibitor, it helps regulate abnormal blood cell formation and reduces the excessive immune signaling that drives disease symptoms.
Rulicent 5 mg is a trusted generic formulation offering the same therapeutic value at a more affordable cost, widely used across hematology centers.
Jakafi is considered a foundational therapy in conditions like myelofibrosis, polycythemia vera (PV), and graft-versus-host disease (GVHD), where it helps reduce discomfort, lower inflammatory markers, and restore patient functioning.
⭐ How
Jakafi (Ruxolitinib) 5 mg – Rulicent Tablets for Myelofibrosis
Works
Abnormal activation of the JAK-STAT pathway leads to uncontrolled blood cell production and chronic inflammation.
Ruxolitinib 5 mg works by:
-
Suppressing overactive JAK1/JAK2 enzymes
-
Managing high red blood cell and platelet counts
-
Reducing spleen enlargement
-
Improving constitutional symptoms (fatigue, night sweats, weight loss)
-
Slowing disease progression
This targeted mechanism provides meaningful improvements in both symptoms and daily functioning.
⭐ Key Benefits of
Jakafi (Ruxolitinib) 5 mg – Rulicent Tablets for Myelofibrosis
-
Effective for myelofibrosis (all risk levels)
-
Controls blood cell overproduction in polycythemia vera
-
Beneficial in acute and chronic GVHD
-
Helps shrink enlarged spleen (splenomegaly)
-
Reduces inflammation-related symptoms
-
Convenient oral tablet for daily therapy
⭐ How to Use
-
Typical initial dose: 5 mg once or twice daily, depending on blood counts and clinical condition
-
Dosage is adjusted based on platelet levels
-
Can be taken with or without food
-
Do not stop treatment suddenly unless advised by a doctor
Frequent blood monitoring is required during therapy.
⭐ Possible Side Effects of
Jakafi (Ruxolitinib) 5 mg – Rulicent Tablets for Myelofibrosis
Common:
-
Low platelet count (thrombocytopenia)
-
Anemia
-
Dizziness
-
Headache
-
Fatigue
Less common but important:
-
Increased infection risk
-
Shingles activation
-
Elevated liver enzymes
Patients should report fever, bleeding, or persistent weakness promptly.
⭐ Who Should Use Jakafi 5 mg
-
Adults diagnosed with myelofibrosis (primary or secondary)
-
Patients with polycythemia vera resistant to hydroxyurea
-
Individuals with steroid-resistant graft-versus-host disease
-
Those requiring targeted JAK inhibition therapy for symptom control
⭐ Storage Instructions
-
Store below 30°C
-
Keep tablets in original blister or bottle
-
Protect from heat and moisture
-
Keep out of children’s reach
